Open AccessLung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report
Author(s) -
Hongbiao Wang,
Sujuan Zhu,
Zhifeng Li,
Xiaofang Qi,
Liwen Zhang,
Leiyu Ke,
Yingcheng Lin
Publication year - 2022
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000030316
Subject(s) - alectinib , medicine , crizotinib , lung cancer , anaplastic lymphoma kinase , adenocarcinoma , oncology , osimertinib , gene rearrangement , gefitinib , erlotinib , cancer research , epidermal growth factor receptor , cancer , gene , malignant pleural effusion , biochemistry , chemistry